Literature DB >> 9630353

Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione.

M P Gordge1, J S Hothersall, A A Noronha-Dutra.   

Abstract

1. We have measured the ability of a range of NO donor compounds to stimulate cyclic GMP accumulation and inhibit collagen-induced aggregation of human washed platelets. In addition, the rate of spontaneous release of NO from each donor has been measured spectrophotometrically by the oxidation of oxyhaemoglobin to methaemoglobin. The NO donors used were five s-nitrosothiol compounds: S-nitrosoglutathione (GSNO), S-nitrosocysteine (cysNO), S-nitroso-N-acetyl-DL-penicillamine (SNAP), S-nitroso-N-acetyl-cysteine (SNAC), S-nitrosohomocysteine (homocysNO), and two non-nitrosothiol compounds: diethylamine NONOate (DEANO) and sodium nitroprusside (SNP). 2. Using 10 microM of each donor compound, mean+/-s.e.mean rate of NO release ranged from 0.04+/-0.001 nmol min(-1) (for SNP) to 3.15+/-0.29 nmol min(-1) (for cysNO); cyclic GMP accumulation ranged from 0.43+/-0.05 pmol per 10(8) platelets (for SNP) to 2.67+/-0.31 pmol per 10(8) platelets (for cysNO), and inhibition of platelet aggregation ranged from 40+/-6.4% (for SNP) to 90+/-3.8% (for SNAC). 3. There was a significant positive correlation between the rate of NO release and the ability of the different NO donors to stimulate intra-platelet cyclic GMP accumulation (r = 0.83; P = 0.02). However, no significant correlation was observed between the rate of NO release and the inhibition of platelet aggregation by the different NO donors (r= -0.17), nor was there a significant correlation between cyclic GMP accumulation and inhibition of aggregation by the different NO donor compounds (r = 0.34). 4. Comparison of the dose-response curves obtained with GSNO, DEANO and 8-bromo cyclic GMP showed DEANO to be the most potent stimulator of intraplatelet cyclic GMP accumulation (P < 0.001 vs both GSNO and 8-bromo cyclic GMP), but GSNO to be the most potent inhibitor of platelet aggregation (P < 0.01 vs DEANO, and P < 0.001 vs 8-bromo cyclic GMP). 5. The rate of NO release from GSNO, and its ability both to stimulate intra-platelet cyclic GMP accumulation and to inhibit platelet aggregation, were all significantly diminished by the copper (I) (Cu+) chelating agent bathocuproine disulphonic acid (BCS). In contrast, BCS had no effect on either the rate of NO release, or the anti-platelet action of the non-nitrosothiol compound DEANO. 6. Cyclic GMP accumulation in response to GSNO (10(-9) 10(-5) M) was undetectable following treatment of platelets with ODQ (100 microM), a selective inhibitor of soluble guanylate cyclase. Despite this abolition of guanylate cyclase stimulation, GSNO retained some ability to inhibit aggregation, indicating the presence of a cyclic GMP-independent component in its anti-platelet action. However, this component was abolished following treatment of platelets with a combination of both ODQ and BCS, suggesting that Cu+ ions were required for the cyclic GMP-independent pathway to operate. 7. The cyclic GMP-independent action of GSNO, observed in ODQ-treated platelets, could not be explained by an increase in intra-platelet cyclic AMP. 8. The impermeable thiol modifying agent p-chloromercuriphenylsulphonic acid (CMPS) produced a concentration-dependent inhibition of aggregation of ODQ-treated platelets, accompanied by a progressive loss of detectable platelet surface thiol groups. Additional treatment with GSNO failed to increase the degree of aggregation inhibition, suggesting that a common pathway of thiol modification might be utilized by both GSNO and CMPS to elicit cyclic GMP-independent inhibition of platelet aggregation. 9. We conclude that NO donor compounds mediate inhibition of platelet aggregation by both cyclic GMP-dependent and -independent pathways. Cyclic GMP generation is related to the rate of spontaneous release of NO from the donor compound, but transfer of the NO signal to the cyclic GMP-independent pathway may depend upon a cellular system which involves both copper (I) (Cu+) ions and surface membrane thiol groups. The potent anti-platelet action of GSNO

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630353      PMCID: PMC1565373          DOI: 10.1038/sj.bjp.0701821

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy.

Authors:  I L Megson; N Sogo; F A Mazzei; A R Butler; J C Walton; D J Webb
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.

Authors:  Séverine Roger; Cécile Badier-Commander; Jérôme Paysant; Alex Cordi; Tony J Verbeuren; Michel Félétou
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

3.  Lack of effect of ODQ does not exclude cGMP signalling via NO-sensitive guanylyl cyclase.

Authors:  Barbara Lies; Dieter Groneberg; Stepan Gambaryan; Andreas Friebe
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

4.  Protein disulfide-isomerase mediates delivery of nitric oxide redox derivatives into platelets.

Authors:  Susannah E Bell; Chirag M Shah; Michael P Gordge
Journal:  Biochem J       Date:  2007-04-15       Impact factor: 3.857

5.  A nanoparticle delivery vehicle for S-nitroso-N-acetyl cysteine: sustained vascular response.

Authors:  Parimala Nacharaju; Chaim Tuckman-Vernon; Keith E Maier; Jason Chouake; Adam Friedman; Pedro Cabrales; Joel M Friedman
Journal:  Nitric Oxide       Date:  2012-06-15       Impact factor: 4.427

Review 6.  S-nitrosothiols as selective antithrombotic agents - possible mechanisms.

Authors:  M P Gordge; F Xiao
Journal:  Br J Pharmacol       Date:  2010-03-08       Impact factor: 8.739

7.  Regulation of platelet granule exocytosis by S-nitrosylation.

Authors:  Craig N Morrell; Kenji Matsushita; Kelly Chiles; Robert B Scharpf; Munekazu Yamakuchi; Rebecca J A Mason; Wolfgang Bergmeier; Joseph L Mankowski; William M Baldwin; Nauder Faraday; Charles J Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-28       Impact factor: 11.205

8.  A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations.

Authors:  Michael S Crane; Adriano G Rossi; Ian L Megson
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

9.  Redox modulation of plant developmental regulators from the class I TCP transcription factor family.

Authors:  Ivana L Viola; Leandro N Güttlein; Daniel H Gonzalez
Journal:  Plant Physiol       Date:  2013-05-17       Impact factor: 8.340

10.  Cyclic GMP-independent mechanisms contribute to the inhibition of platelet adhesion by nitric oxide donor: a role for alpha-actinin nitration.

Authors:  Sisi Marcondes; Marcia H M Cardoso; Rafael P Morganti; Sara M Thomazzi; Sergio Lilla; Ferid Murad; Gilberto De Nucci; Edson Antunes
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.